NeuroDerm

NeuroDerm is a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system (CNS) disorders that will make a clinically meaningful difference in patients’ lives. NeuroDerm’s technology enables new routes of administration for existing drugs that overcome their current deficiencies and achieve enhanced clinical efficacy.

NeuroDerm is the first to develop liquid levodopa (LD), the gold standard treatment for Parkinson’s disease, thus enabling for the first time continuous sub-cutaneous (SC) administration of this drug. By overcoming its biggest deficiency – short half life – NeuroDerm’s products should transform patients’ lives, offering them clinical benefits that can only be obtained today by undergoing highly invasive surgery.

Latest Updates

NeuroDerm Presents Six Posters at the 21st International Congress of Parkinson’s Disease and Movement Disorders

Includes demographic data from the ND0612 trial 006 and complete data from a Phase 1 pharmacokinetic study of ND0701l. > Read More

European Medicines Agency Accepts Design of NeuroDerm’s ND0612 Phase III iNDiGO Efficacy Trial

NeuroDerm announced it has received a Scientific Advice Letter from the EMA accepting the main design elements suggested by NeuroDerm for the amended iNDiGO phase III efficacy trial. > Read More

NeuroDerm CEO to Present at the Jefferies Global Healthcare Conference on June 7, 2017

The company CEO Oded S. Lieberman, PhD will present at the Jefferies Global Healthcare Conference on Wednesday, June 7 at 2:30 pm ET in New York. > Read More

NeuroDerm ND0612H Phase II Trial Results to be Presented in Late-Breaking Session at the 21st International Congress of Parkinson’s Disease and Movement Disorders

Complete data from trial 006 will be showcased in a late-breaking poster session at the 21st International Congress of Parkinson’s Disease and Movement Disorders, June 4-8, 2017, Vancouver, B.C. > Read More

Our Solutions

NeuroDerm is developing a pipeline of products that address deficiencies in current treatments for the growing population of moderate to severe Parkinson’s disease patients. NeuroDerm is the first to develop a liquid formulation of levodopa/carbidopa (LD/CD). Based on this novel formulation, the company has developed a line of LD/CD products administered through a patch-pump or small belt pump to deliver a continuous, controlled dose of LD/CD. The LD/CD line of products includes: ND0612L for moderate Parkinson’s disease patients, ND0612H for severe Parkinson’s disease patients and ND0680 for the small subset of severe Parkinson’s disease patients whose symptoms have advanced to a more acute stage, requiring even higher doses of LD/CD.